Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02493530 · ClinicalTrials.gov registry record · Phase 1

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

A Phase 1 study of Myelofibrosis and Polycythemia Vera, sponsored by Vanderbilt-Ingram Cancer Center.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
5
Study locations

NCT02493530 is a Phase 1 study of Myelofibrosis and Polycythemia Vera that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 60 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (69% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02493530, a Phase 1 study of Myelofibrosis and Polycythemia Vera, has completed, sponsored by Vanderbilt-Ingram Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
5
Study locations

Study Summary

This is a Phase 1, open-label, study of TGR-1202, a PI3K delta inhibitor, administered together with ruxolitinib in patients with myeloproliferative neoplasms (specifically: polycythemia vera, primary myelofibrosis, PPV-MF or PET-MF) and MDS/MPN.

Conditions Studied

Myelofibrosis Polycythemia Vera

Interventions

  • DRUG ruxolitinib
  • DRUG TGR-1202

Study Locations (5)

Arizona

  • Mayo Clinic - Arizona - Phoenix

Colorado

  • University of Colorado Cancer Center - Aurora

Tennessee

  • Vanderbilt-Ingram Cancer Center - Nashville

Texas

  • Mays Cancer Center at University of Texas Health San Antonio - San Antonio

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2015-07
Est. Completion 2024-05
Phase Phase 1

Sponsor

Vanderbilt-Ingram Cancer Center

189 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02493530

The ClinicalTrials.gov registry entry for NCT02493530 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (69% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which ruxolitinib is the first listed.

NCT02493530 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Colorado, Tennessee.

Frequently Asked Questions

What is clinical trial NCT02493530 about?

NCT02493530 is a clinical study titled "TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea". This is a Phase 1, open-label, study of TGR-1202, a PI3K delta inhibitor, administered together with ruxolitinib in patients with myeloproliferative neoplasms (specifically: polycythemia vera, primary myelofibrosis, PPV-MF or PET-MF) and MDS/MPN.

What is the current status of trial NCT02493530?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-07. Estimated completion is 2024-05.

What conditions does trial NCT02493530 study?

This clinical trial studies the following conditions: Myelofibrosis, Polycythemia Vera.

What interventions are being tested in trial NCT02493530?

The interventions under investigation include: ruxolitinib (DRUG), TGR-1202 (DRUG).

Who is sponsoring clinical trial NCT02493530?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02493530 being conducted?

This trial has 5 study locations across Arizona, Colorado, Tennessee, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myelofibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myelofibrosis

All registered trials for this condition

Polycythemia Vera

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.